Header Logo

Connection

EVELINE BARBIERI to Neuroblastoma

Back to Details
This is a "connection" page, showing publications EVELINE BARBIERI has written about Neuroblastoma.
EVELINE BARBIERI
Connection Strength
3.373
Neuroblastoma
  1. Characterization of Persister Cells Provides Insights into Mechanisms of Therapy Resistance in Neuroblastoma. Cancer Discov. 2024 Dec 02; 14(12):2308-2311.
    View in: PubMed
    Score: 0.656
  2. MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma. Nat Commun. 2022 06 28; 13(1):3728.
    View in: PubMed
    Score: 0.554
  3. p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy. Clin Cancer Res. 2017 Nov 01; 23(21):6629-6639.
    View in: PubMed
    Score: 0.396
  4. Histone chaperone CHAF1A inhibits differentiation and promotes aggressive neuroblastoma. Cancer Res. 2014 Feb 01; 74(3):765-74.
    View in: PubMed
    Score: 0.307
  5. A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma. PLoS One. 2013; 8(11):e79843.
    View in: PubMed
    Score: 0.305
  6. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther. 2006 Sep; 5(9):2358-65.
    View in: PubMed
    Score: 0.185
  7. CHAF1A Blocks Neuronal Differentiation and Promotes Neuroblastoma Oncogenesis via Metabolic Reprogramming. Adv Sci (Weinh). 2021 10; 8(19):e2005047.
    View in: PubMed
    Score: 0.130
  8. Restoration of the molecular clock is tumor suppressive in neuroblastoma. Nat Commun. 2021 06 28; 12(1):4006.
    View in: PubMed
    Score: 0.129
  9. The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma. Int J Mol Sci. 2021 Jun 18; 22(12).
    View in: PubMed
    Score: 0.129
  10. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53. Neoplasia. 2021 06; 23(6):624-633.
    View in: PubMed
    Score: 0.129
  11. Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients. JCI Insight. 2018 12 06; 3(23).
    View in: PubMed
    Score: 0.108
  12. NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis. Cell Death Dis. 2015 Aug 06; 6:e1841.
    View in: PubMed
    Score: 0.086
  13. G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic. Cancer Res. 2013 Jul 01; 73(13):4134-46.
    View in: PubMed
    Score: 0.074
  14. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma. Cancer Res. 2011 Jun 01; 71(11):3841-51.
    View in: PubMed
    Score: 0.064
  15. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma. Angiogenesis. 2011 Sep; 14(3):255-66.
    View in: PubMed
    Score: 0.064
  16. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo. Neoplasia. 2009 Aug; 11(8):753-62.
    View in: PubMed
    Score: 0.057
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.